| Autor: |
Zaman GJ; N.V. Organon, Lead Discovery Unit, Oss P.O. Box 20, 5340 BH OSS, The Netherlands. guido.zaman@organon.com, Michiels PJ, van Boeckel CA |
| Jazyk: |
angličtina |
| Zdroj: |
Drug discovery today [Drug Discov Today] 2003 Apr 01; Vol. 8 (7), pp. 297-306. |
| DOI: |
10.1016/s1359-6446(03)02624-2 |
| Abstrakt: |
Historically, pharmaceutical industries have focussed on the discovery of compounds that target the protein products of genes. The intermediary product between gene and protein, consisting of RNA, has remained largely unexplored. Several drugs targeting the rRNA of bacteria have been, however, in clinical use for over half a century. One of these drug classes, the aminoglycoside antibiotics, also targets human rRNA, and have been developed as therapeutics for genetic disorders. Targeting at the RNA level is an economical approach to address non-drugable proteins and targets that have failed to give leads by hits in HTS, as it can build on biological knowledge gathered over years. RNA also offers entirely new opportunities for drug development, such as targeting of non-coding RNA sequences. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full Text from ScienceDirect